Shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) have been given a consensus rating of “Hold” by the five brokerages that are presently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has given a hold recommendation and two have given a buy recommendation to the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $10.83.

ALPN has been the topic of several recent analyst reports. Zacks Investment Research downgraded Alpine Immune Sciences from a “hold” rating to a “strong sell” rating in a report on Thursday, October 26th. ValuEngine upgraded Alpine Immune Sciences from a “strong sell” rating to a “sell” rating in a report on Thursday, November 30th.

Shares of Alpine Immune Sciences (ALPN) traded up $0.14 during midday trading on Friday, hitting $11.35. The stock had a trading volume of 14,200 shares, compared to its average volume of 19,767. The company has a debt-to-equity ratio of 0.05, a quick ratio of 32.38 and a current ratio of 32.38. Alpine Immune Sciences has a 12-month low of $7.20 and a 12-month high of $14.52. The stock has a market capitalization of $157.56 and a P/E ratio of -1.31.

An institutional investor recently bought a new position in Alpine Immune Sciences stock. Sowell Financial Services LLC bought a new stake in shares of Alpine Immune Sciences, Inc. (NASDAQ:ALPN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 15,714 shares of the biotechnology company’s stock, valued at approximately $162,000. Sowell Financial Services LLC owned approximately 0.40% of Alpine Immune Sciences at the end of the most recent quarter.

COPYRIGHT VIOLATION WARNING: “Alpine Immune Sciences, Inc. (ALPN) Given Consensus Rating of “Hold” by Analysts” was published by American Banking News and is owned by of American Banking News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/01/05/alpine-immune-sciences-inc-alpn-given-consensus-rating-of-hold-by-analysts.html.

Alpine Immune Sciences Company Profile

Nivalis Therapeutics, Inc is a pharmaceutical company. The Company focuses on the discovery and development of product candidates for patients with cystic fibrosis (CF). Its drug candidate portfolio consists of multiple compounds, which are designed for oral, intravenous (IV) or inhaled administration.

Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.